Please login to the form below
Incyte
Incyte shares positive results for Opzelura cream in children with atopic dermatitis
Incyte has announced positive topline results from a late-stage study of its JAK inhibitor cream Opzelura (ruxolitinib) in children aged two to 11 years with atopic dermatitis, the most common ... Jim Lee, group vice president, inflammation and
Incyte’s Opzelura cream receives EC approval for non-segmental vitiligo
Incyte’s Opzelura (ruxolitinib) cream has been approved by the European Commission (EC) to treat adults and adolescent patients aged 12 years and older with non-segmental vitiligo with facial involvement. ... vehicle. Hervé Hoppenot, chief executive
Incyte and Biotheryx collaborate to develop protein degraders for oncology targets
Biotheryx will receive up to $347m in potential milestone payments. Incyte and Biotheryx have entered into a research collaboration and licensing agreement to discover and develop protein degraders for ‘historically undruggable’ ... Incyte will then
Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
Eli Lilly and Incyte’s Olumiant (baricitinib) was also approved for emergency use in the US in May 2022, making it the first FDA-approved Janus kinase inhibitor for the treatment
Incyte’s Opzelura shows significant improvements in phase 3 vitiligo trial
Incyte has announced that data taken from its pivotal phase 3 TRuE-V clinical trial programme assessing Opzelura 1.5% cream (ruxolitinib) in patients 12 years and older with nonsegmental vitiligo ... 52. Jim Lee, Incyte’s group vice president,
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
